Pseudomonas aeruginosa is a common and important pathogen in the critically ill. It combines environmental hardiness with genomic plasticity and is well adapted to the various niches available in the intensive care unit (ICU). Unresolved arguments over the value of dual versus monotherapy relate primarily to rapidity of killing and to the avoidance of therapeutic failure due to antibiotic resistance. Increasing resistance to conventional antibiotics means that we need to be aware of the factors that promote the success of this pathogen in the ICU, and of emerging alternative strategies. This review focuses on an understanding of the underlying issues and on the practical aspects of prescribing, particularly in the ICU.
The consideration of pseudomonal infection dominates the prescribing decisions and the development of antibiotic protocols in critical care environments. 1 However, the incidence of pseudomonal infection and of infections due to antibiotic-resistant strains vary from one intensive care unit (ICU) to the next, 2 probably as a reflection of the case mix of patients (and the ecological niches available to the pathogen) and of prescribing practices. 3 Antibiotic resistance in Pseudomonas aeruginosa is the result of a combination of factors ( Table 1 ) that vary in importance with time and place.
WHY IS P. AERUGINOSA SO ANTIBIOTIC RESISTANT? P. aeruginosa has all the key attributes of the gramnegative pathogens that are adapted to the polymicrobial aqueous environment. It has the ability to coordinate its metabolic and virulence systems on the basis of external information (environmental sensing 4, 5 ), it can communicate effectively to members of the same species and even other bacterial species (intercellular signaling or ''quorum sensing'' [5] [6] [7] , and it readily exchanges genetic material such as plasmids, which may provide advantages such as antibiotic or heavy metal resistance. 4, 8 In addition, P. aeruginosa is the archetypal biofilm-forming organism. This is common among bacteria, 5, [9] [10] [11] particularly among the gram-negative bacteria, and is important for two reasons: first, because it is the usual state in which bacteria are found both in nature and in the clinical environment of the high-dependency or critical care unit, and second because the organisms in this state are relatively much less susceptible to antibiotics that target bacterial growth and cell division.
Bacteria are adapted to living on the edge of existence, in a biological state that preserves DNA at the expense of cellular activity. 12, 13 The response to normal environmental stress in gram-negative bacteria might be thought of as similar in evolutionary/biological function to that of the bacterial spore produced by gram-positive bacteria such as Clostridium spp.
When an opportunity arises, persisting cells with high DNA:cytoplasmic ratios and low cellular activity levels are able to exponentially reexpand the bacterial population.
The clinical implications are best illustrated in the infected central venous catheter. A P. aeruginosa biofilm containing stressed organisms in this metabolically stringent state (typically with an additional protective exopolysaccharide matrix secreted by the bacteria) may require concentrations of antibiotics, such as gentamicin, that are up to a thousandfold higher than those levels issued by the diagnostic laboratory that has cultured and tested their exponentially growing progenitors or progeny and defined them as ''sensitive. '' 10,14 The antibiotic quickly kills actively growing organisms, but persistent physiologically inert members of the population in the biofilm offer few antibiotic targets and survive to cause relapse. Similarly, defervescence occurs after only a few days of therapy for heart valve infections, but weeks of therapy are required for definitive cure.
Another attribute of P. aeruginosa that makes it particularly likely to be antibiotic resistant is its genomic size and flexibility. The P. aeruginosa genome is among the largest among the eubacteria, and, although it participates in the general gene pool by genetic exchange, it also encodes for a range of membrane pumps and transporters. These allow it to manage environmental toxins such as heavy metals, and have been readily adapted to managing antibiotics. Indeed, for certain antibiotics such as the carbapenems, membrane exclusion (e.g., for imipenem) and active efflux (e.g., for meropenem) may be more important than carbapenemhydrolyzing enzymes. The ability to restrict the access of antibiotics to bacterial target sites in this way also means that relatively less potent hydrolyzing enzymes are particularly effective in P. aeruginosa. For smaller gramnegative organisms not equipped to manage the access of substances across the outer membrane in this way, an efficient carbapenem-hydrolyzing enzyme is probably only effective in the presence of an additional membrane defect. Because these traits are commonly transmissible, this has particular applications for infection control in critical care environments. 15, 16 DO WE NEED TWO-DRUG THERAPY FOR P. AERUGINOSA INFECTION?
Prevention of Antibiotic Resistance Antibiotic therapy selects for the expansion of resistant subpopulations by eradication of competitors from within a biological niche, and combination therapy is advised at least in part to reduce the likelihood of developing antibiotic resistance. 1 Resistance to important modern antibiotics may be observed after a single exposure 15 or during the course of therapy, 17 and the effects of antibiotic exposure on bacterial populations are well described. 18 The use of multiple drugs to minimize the emergence of resistant subpopulations is familiar to all who deal with tuberculosis, in which drug resistance is an important feature of relapse. 19 However, there is little evidence at present for a real clinical impact of this approach in the setting of acute severe sepsis. This is not unexpected for the following reasons: P. aeruginosa is typically an opportunistic invader and except in special cases (see the later section on cystic fibrosis), infection associated with acute severe sepsis is likely to be clonal (i.e., all the infecting bacterial cells are identical). Thus it is unlikely that unknown subpopulations of resistant organisms will arise in the short time (the first 72 hours) crucial to the control of septic shock. This statement is most valid where a single heritable stable resistance mechanism exists (e.g., a chromosomally encoded aminoglycosidemodifying enzyme) and least valid where the mechanism is potentially inducible (e.g., porin-mediated or effluxmediated carbapenem resistance) or readily acquired by plasmid transfer. Even so, this would not be expected to occur during the course of managing the acute vegetative infection. It is primarily those organisms Hydrolyzing enzymes þ (emerging) Decreased porin permeability (e.g., imipenem) efflux pumps (e.g., meropenem) -All* Biofilms/stringent state -*Antibiotics that target growth and cell division (e.g., b-lactams, carbapenems, and aminoglycosides) are most effective against vegetative (rapidly growing) organisms.
OPTIMIZING ANTIPSEUDOMONAL THERAPY/IREDELL that are partially protected and exposed to concentration gradients in wounds and biofilms (catheters, airways, burns, etc.) which have the opportunity to adapt and evolve efficiently. Thus a resistant late relapse or apparent second infection 1 or 2 weeks later is much less surprising, 2 especially in the setting of high infective burdens. Some authorities therefore recommend twodrug therapy for this reason, 2 and especially for this pathogen, because it is one of the most successfully adapted to forming biofilms in the critical care environment (equipment, drains) or patient (catheters, wounds) and one of the most likely to have an antibiotic resistance mechanism that is already active or inducible or can be readily acquired.
This sets up an apparent paradox: it follows that combination therapy with two agents to which the pathogen is susceptible in vitro is probably least important in preventing resistance in serious infections such as bacteremias where there is a removable or extinguishable focus, but most important where there is a large burden of pathogens that may not be causing extremely serious disease (e.g., airway or wound infections). The important caveat here is that the two drugs must be effectively co-available at the tissue level. Thus the pharmacokinetics and pharmacodynamics of drug delivery to sites like wounds and lung and airways are crucial determinants of this outcome. To pursue the example of airway infection treated in the ICU by combination b-lactam/ aminoglycoside therapy, poor penetration by aminoglycosides will tend to mimic the effects of monotherapy or, possibly worse, expose the pathogens to sublethal drug levels.
Improved Antimicrobial Spectrum
Second, resistance to the antipseudomonal penicillin/ b-lactamase inhibitor combinations (e.g., ticarcillin/ clavulanate; piperacillin/tazobactam) and even to the carbapenems (e.g., imipenem, meropenem) has been rising. The addition of another agent that extends the spectrum further has obvious value. Most intensivists like to be at least 90% confident that their antimicrobial coverage is complete in the setting of critical sepsis. The decision to use two-drug therapy for this reason needs to be entirely based on information on local antimicrobial susceptibility data, which, although generally acknowledged as valuable, is not always readily available. 20 All the foregoing caveats apply, but where there is doubt that a single agent will cover at least 90% of possible pathogens, it is rational to employ a second drug aimed at increasing that spectrum of activity to > 95%.
Synergistic Activity
Finally, there is evidence for in vitro synergistic activity of a range of agents, particularly cell-wall-active agents such as the b-lactams (penicillins, cephalosporins) and carbapenems (e.g., meropenem) in combination with aminoglycosides (e.g., gentamicin) and quinolones (e.g., levofloxacin, ciprofloxacin), 2,21-23 although careful meta-analyses do not adduce a clinical benefit in combination therapy for sepsis, including neutropenics and the subgroup of pseudomonal infection, 24 and adverse effects such as nephrotoxicity were more common in combination therapy. It is noteworthy that early evidence for improved outcomes in staphylococcal bacteremia and endocarditis from b-lactam/aminoglycoside combination therapy showed that the advantage was most evident early in therapy and that increased toxicity only arose after several days.
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The idea remains intuitively appealing in those who are most ill, where effective early antimicrobial 26, 27 and goal-directed resuscitative therapy 28 is crucial. There is now published evidence to suggest that in the patient with shock, combination antibiotic therapy may be associated with decreased 28-day mortality. 29 It may be that combining two effective agents (e.g., b-lactam/ aminoglycoside) is only of value in a limited subgroup, or that the lesser toxicity of the quinolones may be preferable.
In conclusion, combination therapy should be employed when it is required to increase the spectrum of activity to acceptable levels. It is doubtful that it has great value in preventing development of resistance except in prolonged treatment of high-burden infections, in which pharmacodynamic and pharmacokinetic considerations are paramount. 30, 31 Finally, although the data are a little conflicting, it seems rational to employ synergistic combinations of b-lactams with aminoglycosides or quinolones in early therapy for serious P. aeruginosa infection, 32,33 but ongoing therapy with two active agents after the first few days is probably inferior to optimized monotherapy. A study comparing the value of combination therapy in the first 72 hours only, with monotherapy from the outset, is needed to resolve this.
ARE SOME DRUGS PREFERABLE TO OTHERS?
The antipseudomonal penicillin/b-lactamase inhibitor combinations (ticarcillin/clavulanate and piperacillin/ tazobactam) remain the core of most sepsis regimens, to which aminoglycosides (to enhance spectrum and/ or provide synergy) and/or glycopeptides (particularly targeting methicillin-resistant staphylococci) are commonly added.
The later-generation cephalosporins (e.g., cefepime) appear to be equivalent in efficacy in vitro, and resistance is still unusual, but it is not yet clear whether these are more likely than regimens with an antipseudomonal penicillin at its core to select for antibiotic resistance in the microflora as a whole. Data from our own ICU have shown that 3-month periods in which cefepime is used predominantly may be associated with more ICU-acquired infections due to P. aeruginosa and methicillin resistant Staphylococcus aureus (MRSA) than matched 3-month periods in which cefepime is replaced by piperacillin/tazobactam (unpublished data).
The fluoroquinolones are a popular choice for antipseudomonal regimens, with excellent pharmacological and safety profiles and good evidence for synergy with b-lactams. 23 The incremental nature of resistance acquisition 34 and their track record in selecting antibiotic resistance within the microflora 35 have made them less popular choices, and the quinolones and third-generation cephalosporins are specifically restricted in ICU prescribing guidelines in many countries. 36 Nevertheless, they are less likely on first principles to induce resistance than is an aminoglycoside (with poorer penetration to lung and airways), when combined with a b-lactam for ventilator-associated pneumonia. The quinoloneb-lactam combination appears to superior in other serious infections such as neutropenic sepsis. 32 The extent to which this relates to spectrum (e.g., coverage > 95%), activity (e.g., faster killing as individual agents and/or in synergy), and/or resistance development is unclear (although evidence for increased superinfections in monotherapy is lacking 24 ), and the generalizability of this therefore remains uncertain.
On balance, the antipseudomonal penicillin/blactamase inhibitor combinations should therefore retain their position of primacy, with the later-generation cephalosporins and the carbapenems regarded as ''reserve'' agents in resistant infections. Synergistic combinations should be simplified to the narrowest-spectrum agent as soon as possible when directed therapy is feasible and control of the initial infection has been achieved. Where information is lacking and therapy is protocol driven, the necessity to use multiple agents should be determined primarily on the basis of local antimicrobial susceptibility patterns.
SPECIAL CIRCUMSTANCES AND FUTURE OPTIONS
Antibiotic Combinations for Multiply Antibiotic-Resistant P. aeruginosa The key antibiotics in the critical care environment have for some time been the antipseudomonal penicillins and cephalosporins, the antipseudomonal carbapenems, the aminoglycosides, and the quinolones. The new glycylcycline antibiotic tigecycline is ineffective as an antipseudomonal, and new cephalosporins and carbapenems are potentially valuable, as are combinations of older drugs, including rifampicin, polymyxin, b-lactams, and b-lactamase inhibitors-these are reviewed in this issue and in recent publications. 30, 33 The natural tendency for transmissible antibiotic resistance genes to be coinherited means that single-gene-encoded mechanisms (e.g., enzymes that modify b-lactam and aminoglycoside antibiotics) will increasingly be found together, and this will be apparent in local epidemiological profiles. The more difficult resistance mechanisms are those that may be incrementally acquired and be relatively ''silent'' until established-the quinolones are the archetypal example of this 34 and are thus unpopular in closed microcosms such as ICUs. 36 Cystic Fibrosis Disease progression in cystic fibrosis (CF) is determined almost solely by infection, and P. aeruginosa remains the dominant pathogen. 37 Bacterial ''mucoidy'' develops soon after establishment of infection, as a result of upregulated exopolysaccharide production, and chronic infection in biofilms means greatly reduced antimicrobial efficacy. 14 In addition, the subpopulations of P. aeruginosa in the CF patient become increasingly heterogeneous over time due to microevolution in different niches within the damaged lung. An important part of this evolution is the frequent presence of DNA mismatch repair mutants (''hypermutators''), which are in turn more likely to generate spontaneous mutations associated with antibiotic resistance. 38, 39 The unique biology of P. aeruginosa in CF has meant that antimicrobial eradication is generally unsuccessful. 37 New approaches are important here and may also provide us with clues in non-CF infections due to P. aeruginosa, especially those associated with other biofilms such as catheter infections and ventilatorassociated pneumonia in the ICU.
Synergistic Activity of Aminoglycosides and Ion-Channel Inhibitors
Nebulized tobramycin is the only accepted mode of therapy for P. aeruginosa infection in the CF lung at present. 37 However, it was recognized some time ago that the sodium-channel blocker amiloride in combination with tobramycin may have marked bactericidal activity against P. aeruginosa and especially the less common but more problematic B. cenocepacia. 40 A recent clinical pilot study showed promising results with eradication of B. cepacia in several CF patients, 41 and follow-up in vitro studies have shown that the amiloride analogue, benzamil, is even more efficacious against both B. cenocepacia and P. aeruginosa (Treerat P, George AM, Iredell J, Middleton P, Widmer F, unpublished data).
Bacteriophage Therapy
Bacteriophage therapy has a long history 42 and has been turned to again more recently, with some evident OPTIMIZING ANTIPSEUDOMONAL THERAPY/IREDELL promise. 43, 44 Bacteriophage therapy requires identification of a lytic bacteriophage active against the given strain, which can be identified from a suitable library given sufficient time and appropriate expertise for matching phage to bacterium. Because this is a natural predator-prey relationship, 45 evolution and selection of resistant subpopulations can be expected to be at least as efficient as development of antibiotic resistance. Some of these inherent difficulties may be overcome in the future by development of bacteriophage cocktails of several bacteriophages with high activity against all or most local isolates.
Quorum Sensing Inhibitors
The importance of intercellular signaling (''quorum sensing'') molecules in the regulation of biofilm formation and virulence 5, 7 has driven attempts to develop molecules that directly inhibit these actions. These small messenger molecules (typically homoserine lactones) can be chemically modified or directly manufactured, and this area of research holds considerable promise. [46] [47] [48] Because these systems of messenger molecules and receptors are essential to normal population functioning in bacteria and are incompletely understood at present, the extent to which compensatory or resistance mechanisms will be able to overcome direct inhibition is unknown. However, once delivery of these molecules is solved, catheters and implantable devices impregnated with quorum-sensing inhibitors that prevent or delay formation of biofilms may become the standard of care.
CONCLUSIONS
It is clear from first principles that P. aeruginosa will remain a highly adapted nosocomial pathogen, and that this adaptation will always include resistance to antimicrobial agents. Optimal management consists of accurate and aggressive prescribing in severe infection, and avoidance of unnecessary antibiotic exposure which leads to development of further resistance and/or elimination of competitive microflora. The most difficult question remains whether combining cell-wall-active drugs such as b-lactams with intracellular poisons such as aminoglycosides or quinolones is advantageous in the treatment of pseudomonal infection. This is not generally true, but there is a theoretical basis and limited evidence in favor of brief synergistic combination therapy in the initial management of the patient with severe sepsis. Future options for extending the spectrum against highly antibiotic-resistant strains will include antibiotic drug combinations and adjunctive approaches such as bacteriophage and quorum-sensing inhibition, as well as potentially new drug targets (such as ion channel inhibitors). 
